Finally, DOT1L inhibition has also been assessed in NPM1 mutant AML and resulted synergistic with menin–MLL inhibitors in suppressing HOX, MEIS1, and FLT3 gene expression and inducing AML cell differentiation (61). Here, KMT2A is linked to acute myeloid leukemia.